The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year
Budesonide is indicated for mild to moderate active Crohn's disease involving the ileum and/or the ascending colon in adults and children 8 years of age and olde
The ALLEGORY study demonstrated statistically significant improvements in key measures, including British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response
Building on the Merck Foundation’s longstanding commitment to advancing access to high-quality health care, new national initiative supports grants to 11 organizations across the country
The upcoming state-of-the art 400+ bed facility is set to come up at an approximate cost of Rs 500 crore
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
The FW500 is designed to meet the evolving needs of mid-sized diagnostic laboratories
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Subscribe To Our Newsletter & Stay Updated
